title: Cost savings of patients with a MACIS score lower than 6 when radioactive iodine is not given.
abstract: OBJECTIVE
  To assess the cost savings if the current policy of treating patients with a MACIS (metastases, age, completeness of resection, invasion, and size) score lower than 6 using radioactive iodine (RAI) was changed to reflect the findings of recent studies.
  
  
  METHODS
  Retrospective medical record review.
  
  
  METHODS
  Mount Sinai Hospital, Toronto, Ontario.
  
  
  METHODS
  Between January 1, 2002, and July 1, 2005, 199 consecutive patients with a MACIS score lower than 6 who received RAI treatment after total thyroidectomy.
  
  
  METHODS
  Patient demographics were analyzed. Costs for the dose of RAI, hospital stay, and health insurance claims were included in the calculations.
  
  
  RESULTS
  For 199 consecutive patients, the cost for sodium iodide 131 treatment totaled Can$161 588, and the required 2-day stay in isolation totaled Can$764 558. The overall cost to the health care system was Can$934 106, which translates into approximately Can$4694 per patient.
  
  
  CONCLUSIONS
  By following the recommendations of recent evidence-based studies and by ceasing to treat patients with a MACIS score lower than 6 after total thyroidectomy using RAI, cost savings can be accrued for health care systems involved in the treatment of thyroid cancer. Alternate strategies, such as treating patients who need RAI therapy on an outpatient basis and reducing the dose of RAI, can lower costs as well.
authors: Department of Otolaryngology, Mount Sinai Hospital, 600 University Avenue, Toronto, Ontario, Canada. ppaceasc@hotmail.com
authors: Pia Z
authors: PZ
authors: Pace-Asciak
authors: Richard J
authors: RJ
authors: Payne
authors: Spiro J
authors: SJ
authors: Eski
authors: Paul
authors: P
authors: Walfish
authors: Manzur
authors: M
authors: Damani
authors: Jeremy L
authors: JL
authors: Freeman
mesh_terms: D018263:Adenocarcinoma, Follicular / Q000191:economics* / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D000231:Adenocarcinoma, Papillary / Q000191:economics* / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D000293:Adolescent; D000328:Adult; D000368:Aged; D003131:Combined Modality Therapy / Q000191:economics; D017046:Cost Savings; D019317:Evidence-Based Medicine / Q000191:economics; D005260:Female; D017721:Hospital Costs / Q000706:statistics & numerical data; D006801:Humans; D007457:Iodine Radioisotopes / Q000191:economics* / Q000627:therapeutic use; D007902:Length of Stay / Q000191:economics; D008297:Male; D008875:Middle Aged; D009313:National Health Programs / Q000191:economics*; D009361:Neoplasm Invasiveness; D009864:Ontario; D018714:Radiotherapy, Adjuvant / Q000191:economics; D012189:Retrospective Studies; D012720:Severity of Illness Index; D013964:Thyroid Neoplasms / Q000191:economics* / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D013965:Thyroidectomy / Q000191:economics*
chemical_list: D007457:Iodine Radioisotopes